Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

被引：1
|
作者：
Bouwhuis, M. G.
Suciu, S.
Testori, A.
Santinami, M.
Kruit, W. H.
Punt, C. J.
Sales, F.
Patel, P. M.
Spatz, A.
Eggermont, A. M. M.
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[2] EORTC Data Ctr, Dept Biostat, Brussels, Belgium
[3] European Inst Oncol, Milan, Italy
[4] Natl Canc Inst, I-20133 Milan, Italy
[5] Univ Med Ctr Nijmegen, Nijmegen, Netherlands
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[8] Inst Gustave Roussy, Villejuif, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70098-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5LB
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [41] Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    Daud, A. I.
    Xu, C.
    Hwu, W. -J.
    Urbas, P.
    Andrews, S.
    Papadopoulos, N. E.
    Floren, L. C.
    Yver, A.
    DeConti, R. C.
    Sondak, V. K.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 657 - 666
  • [42] Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients' and doctors' views
    Loquai, Carmen
    Schmidtmann, Irene
    Beutel, Manfred
    Sunderkoetter, Cord
    Grabbe, Stephan
    Schiller, Meinhard
    Nashan, Dorothee
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2011, 21 (06) : 976 - 984
  • [43] Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
    Chevolet, Ines
    Schreuer, Max
    Speeckaert, Reinhart
    Neyns, Bart
    Hoorens, Isabelle
    van Geel, Nanja
    Kruese, Vibeke
    Hennart, Benjamin
    Allorge, Delphine
    Van Gele, Mireille
    Brochez, Lieve
    [J]. MELANOMA RESEARCH, 2015, 25 (04) : 357 - 361
  • [44] Randomized Trial Comparing Pegylated Interferon α-2b Versus Pegylated Interferon α-2a, Both Plus Ribavirin, to Treat Chronic Hepatitis C in Human Immunodeficiency Virus Patients
    Laguno, Montserrat
    Cifuentes, Carmen
    Murillas, Javier
    Veloso, Sergio
    Larrousse, Maria
    Payeras, Antoni
    Bonet, Lucia
    Vidal, Francesc
    Milinkovic, Ana
    Bassa, Antoni
    Villalonga, Concha
    Perez, Inaki
    Tural, Cristina
    Martinez-Rebollar, Maria
    Calvo, Marta
    Luis Blanco, Jose
    Martinez, Estaban
    Sanchez-Tapias, Jose M.
    Gatell, Jose M.
    Mallolas, Jose
    [J]. HEPATOLOGY, 2009, 49 (01) : 22 - 31
  • [45] The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.
    Versluis, Judith M.
    Blankenstein, Stephanie
    Dimitriadis, Petros
    Sanders, Joyce
    Hoefakker, Willem
    Broeks, Annegien
    Van Houdt, Winan J.
    Schrage, Yvonne M.
    Wouters, Michel W. J. M.
    Van Akkooi, Alexander Christopher Jonathan
    Blank, Christian U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Phase I trial of pegylated interferon-α-2b in young patients with plexiform neurofibromas
    Jakacki, R. I.
    Dombi, E.
    Potter, D. M.
    Goldman, S.
    Allen, J. C.
    Pollack, I. F.
    Widemann, B. C.
    [J]. NEUROLOGY, 2011, 76 (03) : 265 - 272
  • [47] Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial
    Egberts, F.
    Gutzmer, R.
    Ugurel, S.
    Becker, J. C.
    Trefzer, U.
    Degen, A.
    Schenck, F.
    Frey, L.
    Wilhelm, T.
    Hassel, J. C.
    Schadendorf, D.
    Livingstone, E.
    Mauch, C.
    Garbe, C.
    Berking, C.
    Rass, K.
    Mohr, P.
    Kaehler, K. C.
    Weichenthal, M.
    Hauschild, A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (07) : 1667 - 1674
  • [48] Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Rutkowski, Piotr
    Kruit, Willem H.
    Punt, Cornelis J.
    Dummer, Reinhard
    Sales, Francois
    Keilholz, Ulrich
    de Schaetzen, Gaetan
    Testori, Alessandro
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 55 : 111 - 121
  • [49] Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients
    Weichenthal, Michael
    Chiarion-Sileni, Vanna
    Hauschild, Axel
    Del Bianco, Paola
    Trefzer, Uwe
    Guida, Michele
    Enk, Alexander
    Romanini, Antonella
    Loquai, Carmen
    Ridolfi, Ruggero
    Schadendorf, Dirk
    Mandala, Mario
    Koller, Josef
    Silvestri, Barbara
    Gogas, Helen
    Medici, Michele
    Dummer, Reinhard
    De Salvo, Gian Luca
    Mohr, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] A phase I & II trial of peri-operative adjuvant interleukin-2 and interferon alfa 2b in patients with melanoma
    Zapas, JL
    Elias, EG
    Beam, SL
    Picard, DL
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (01) : S20 - S20
12345